NASDAQ · Biotechnology

Nurix Therapeutics, Inc. (NRIX) Stock

$22.35 +0.63% NASDAQ: NRIX Healthcare

Valuation

MetricValue
Price$22.35
Market Cap$2.32B
P/E Ratio-6.61
P/B Ratio6.29
P/S Ratio64.36
EPS (TTM)$-2.86
52-Week High$28.23
52-Week Low$9.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-76.09%
ROA-63.74%
ROCE-77.92%
Gross Margin-1.39%
Operating Margin-4.39%
Net Margin-928.44%
Debt/Equity0.14
Current Ratio7.06

Annual Financials (USD)

Metric20212022202320242025
Revenue$30.0M$39.0M$77.0M$55.0M$84.0M
Operating Profit$-118.0M$-184.0M$-155.0M$-213.0M$-286.0M
Net Profit$-117.0M$-180.0M$-144.0M$-194.0M$-264.0M
EPS$-2.73$-3.71$-2.65$-2.88$-3.05
Op Margin-396.3%-476.0%-201.4%-390.5%-340.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$477.0M$417.0M$356.0M$669.0M$688.0M
Total Liabilities$134.0M$113.0M$155.0M$142.0M$149.0M
Cash$81.0M$64.0M$55.0M$110.0M$247.0M
Borrowings$13.0M$12.0M$31.0M$28.0M$56.0M

Latest News

Mizuho Raises Price Target on Nurix Therapeutics to $34 From $30, Keeps Outperform Rating MT Newswires · Jul 13, 2026 Company News for July 13, 2026 Zacks · Jul 13, 2026 Nurix Therapeutics' Roche Deal Seen Driving Long-Term Upside, RBC Capital Markets Says MT Newswires · Jul 10, 2026 Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates Zacks · Jul 9, 2026 Nurix Therapeutics Q2 Loss Widens, Revenue Falls MT Newswires · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-84.0M$-160.0M$-81.0M$-173.0M$-249.0M
Investing Cash Flow$-114.0M$15.0M$60.0M$-267.0M$134.0M
Financing Cash Flow$4.0M$98.0M$0$7.0M$0
Net Cash Flow$-39.0M$-15.0M$-10.0M$55.0M$137.0M
Free Cash Flow$-90.0M$-172.0M$-90.0M$-182.0M$-263.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.25
EV / EBITDA-7.37
FCF Yield-12.87%
Quick Ratio6.34
Interest Coverage0.00
Return 1Y109.78%
Return 3Y134.36%
Return 5Y-23.18%

Ownership

Insiders Held1.08%
Institutions Held114.44%
Institutions Float Held115.69%
Institutional HolderSharesReport Date
Blackrock Inc.8,925,6422026-03-31
Redmile Group, LLC7,732,8082026-03-31
Vestal Point Capital, LP6,500,0002026-03-31
Deep Track Capital, Lp6,345,2442026-03-31
FMR, LLC5,541,2712026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. is led by CEO Arthur T. Sands, employs 286 people, headquartered in US, publicly traded since 2020.

Nurix Therapeutics, Inc. (NRIX) stock trades at $22.35 with a market capitalization of $2.32B. The stock is valued at a price-to-earnings (P/E) ratio of -6.61, price-to-book of 6.29, price-to-sales of 64.36. Over the past 52 weeks the stock has ranged between $9.00 and $28.23, and currently trades 20.8% below its 52-week high.

On profitability, Nurix Therapeutics, Inc. generates a return on equity (ROE) of -76.09%, return on capital employed of -77.92%, an operating margin of -4.39%, a net profit margin of -928.44%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides